On this website
Utility
Appearance
RSS feed
Accessibility
Recently updated 1document
HIV-1 Tat vaccine results of the phase II trial in South Africa
A phase II clinical trial conducted in South Africa has confirmed that the therapeutic Tat vaccine against HIV/AIDS can effectively improve the response to antiretroviral drugs in people living with HIV. The results are published today in the peer-review open access journal Retrovirology: HIV-Tat immunization induces cross-clade neutralizing antibodies and CD4+ T-cell increases in antiretroviral-treated South African volunteers: a randomized phase II clinical trial
Retrovirology 2016
doi: 10.1186/s12977-016-0261-1
After embargo, article is available at journal website here: http://retrovirology.biomedcentral.com/articles/10.1186/s12977-016-0261-1
2documents
Improving the effect of HIV drugs by the use of a vaccine
A vaccine containing a protein necessary for virus replication can boost an HIV-infected patient’s immune system, according to clinical research published in the open access journal Retrovirology. This boost can result in increased effectiveness of antiretroviral drugs.
1document
State of Art of Anti-HIV/AIDS Vaccine Clinical Trials - update on 1/04/2014
State of Art of Anti-HIV/AIDS Vaccine Clinical Trials based on the recombinant biologically active HIV-1 Tat protein sponsored by ISS updated on april 1st 2014.
About us
Our aim is fighting HIV/AIDS and associated syndromes by developing vaccines and new therapeutic approaches based on studies of the pathogenic mechanisms of HIV infection and progression. The NAC organization reflects the aim to put into effect a “translational” research.
1document
BARBARA ENSOLI WAS APPOINTED AMONG THE NEW MEMBERS OF THE ERC
Barbara Ensoli, Director of the National AIDS Center- ISS, was appointed among the new members of the European Research Council (European Research Council,...
